Archive

Archived articles

Webinar – Safety of Antimalarials (07 October 2014)

The ACT Consortium will be hosting a webinar on the “Safety of Antimalarials”, hosted by Prof David Lalloo of the Liverpool School of Tropical Medicine. This will be on Tue 07 October at 12:30 BST. Full details are available at www.actconsortium.org/webinars.
Continue Reading →

The Risks of the Sustainable Development Goals

The recent opening of the United Nations General Assembly represents a key milestone in the development of the Sustainable Development Goals (SDGs), which will take over from the Millennium Development Goals (MDGs) at the start of 2016. In front of the Assembly will be the Outcome Doc
Continue Reading →

Sanofi Pasteur announce results of Ph. 3 dengue vaccine trial

On 03 September, Sanofi Pasteur announced in a press release the preliminary results of a Phase 3 study of their tetravalent dengue vaccine in Latin American children. It showed an overall reduction in disease cases of 61%, with efficacy against the four serotypes as: Type 1 – 50%, 2
Continue Reading →

Where to invest best in global health?

Every week, the BBC Radio Four programme More or Less points out the use and misuse of statistics*. For TMPC it is compulsory listening. The More or Less presenters respond to questions about the statistics that are used by politicians, in the media, or in other published sources and
Continue Reading →

Making the Business Case for Malaria Investment

We live in a world where resources to control and eliminate the major communicable diseases are being spread widely and possibly too thinly. One of the major successes of the Millennium Development Goals was the focus on a few target diseases – malaria, HIV/AIDS, and tuberculosi
Continue Reading →

Making the Sustainable Development Goals Workable

Today’s NY Times website has a very perceptive article about the risks that the world is running with the current thinking about the Sustainable Development Goals (SDGs). Abhijit Banerjee  and Varad Pande have raised some really serious concerns about what the SDGs will ultimate
Continue Reading →

RTS,S – latest clincial results published

The RTS,S Clinical Trials Partnership have just published the results of the 18 month follow-up on protective efficacy of the GlaxoSmithKline (GSK) malaria vaccine RTS,S/AS01. These results have been eagerly awaited as they will be pivotal data for GSK in its regulatory submission for
Continue Reading →

KAE609 – a game-changer for malaria treatment?

Nick White and colleagues have recently published in New England Journal Of Medicine the results of a Phase 2 open-label study of the new spiroindolone KAE609 (cipargamin). This is a new class of anti-malarials developed at the Novartis Institute for Tropical Diseases in Singapore. Th
Continue Reading →

Artemisinin Conference 2014

The 2014 Artemisinin Conference will be held 23-24 September in Guangzhou, China. This annual meeting has become the key point of contact and co-ordination between the various stakeholders in the artemisinin supply chain, especially between the growers/extractors and those who will es
Continue Reading →